The path to precision medicine
Pharma companies are evaluating their blockbuster or product only strategy. ‘Beyond the pill thinking’ became key to compete. Governments are pushing for proven outcomes. With outcomes come prevention and an individualized patient approach.
If you mention ‘individualized’, you mention ‘data platforms’. This is why companies such as Google or Amazon are appearing on the healthcare scene.
They hold incredible amounts of data. If this data is combined with genetic data, progress can be made with an hyper-personalized approach for each patient.
Patients must take some responsibility too
Patients, too, must assume their responsibilities. Patients can, for example, demonstrate their medication regime or diet using a medical app. At the same time, pharmaceutical companies or health service providers will only be allowed to supply health insurers if they can demonstrate that the patient’s outcome improves significantly. They will evolve in variable contracting with governments.
This way of working has yet to be established in Belgium but is already reality in the US. There, individuals or companies sign a health care contract often making medical treatment twice as efficient.
Medical treatments can become twice as effective if sufficient effort is made to monitor patient behaviour, such as the following of a diet or the taking of medication. A hyper-personalized approach using big data by insurance companies, combined with genetic data, opens up many new perspectives in the field of precision medicine.
Building a new ecosystem together with start-ups
Start-ups and scale-ups have the drive to invent and launch innovative projects. EY has a great deal of expertise that can be used to match up these ambitious companies with larger companies. We also act as a link between pharmaceutical companies and governments, for example to validate the efficacy of a medicine.
In any event, policymakers and life sciences companies in Europe need to broaden their horizons. What is needed is a new ecosystem with more personalized medicine and more clinical studies that look for broad variation in the research population.
Pointellis: a high-way of medical data
Together with Microsoft, EY has developed the solution ‘Pointellis’. This solution can best be compared to a kind of highway of medical data that – in a safe and protected environment – can be exchanged between hospitals, laboratories, pharmaceutical companies and other partners in the medical sector.
When cancer patients have come to the end of their treatment doctors replace classical therapies with experimental cell & gene therapies. DNA cutting and pasting, in order to correct genetic errors. However, this global approach requires a very rapid response and a high level of safety. This is where Pointellis comes in.